Help
RSS
API
Feed
Maltego
Contact
Domain > ir.avalotx.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-10-06
3.221.176.71
(
ClassC
)
2021-12-25
52.23.24.89
(
ClassC
)
2022-02-17
3.225.74.242
(
ClassC
)
2026-01-04
54.183.47.117
(
ClassC
)
2026-01-17
13.56.61.5
(
ClassC
)
2026-02-24
52.52.175.53
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Sun, 04 Jan 2026 11:40:27 GMTServer: ApacheStrict-Transport-Security: max-age31536000; includeSubDomains; preloadX-Frame-Options: SAMEORIGINX-XSS-Protection: 1; modeblockX-Content !DOCTYPE html>html langen>head> meta http-equivx-ua-compatible contentieedge> meta charsetutf-8> link relalternate typeapplication/rss+xml titleAvalo Therapeutics, Inc. - Recent News hrefhttps://ir.avalotx.com/news-events-presentations/press-releases/rss /> title>Avalo Therapeutics, Inc. (AVTX)/title> link relcanonical hrefhttps://ir.avalotx.com>meta propertyog:url contenthttps://ir.avalotx.com>meta propertyog:site_name contentAvalo Therapeutics, Inc.>meta propertyog:title contentOverview>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/379/1737/social_image_resized.jpg>meta nametwitter:card contentsummary_large_image>meta propertyog:description contentAvalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.>meta namedescription contentAvalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.>script typeapplication/ld+json> {@context:http://schema.org,@type:Corporation,name:Avalo Therapeutics, Inc.,address:{@type:PostalAddress,streetAddress:1500 Liberty Ridge Drive Suite 321,addressLocality:Wayne, PA,postalCode:19087,addressCountry:},legalName:Avalo Therapeutics, Inc.,description:Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalou2019s lead asset is AVTX-009, an anti-IL-1u03b2 mAb, targeting inflammatory diseases.,tickerSymbol:: AVTX,url:https://ir.avalotx.com,logo:https://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/logo.png,image:https://d1io3yog0oux5.cloudfront.net/_c309696b5c05580c5a8a24e40542c298/avalotx/db/379/1737/social_image_resized.jpg,sameAs:}/script>!-- Elastic Sear
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]